Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0533 versus pioglitazone in adults with type 2 diabetes mellitus and inadequate glycemic control
2006-002090-47Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of MK-0533 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Total body water, Fasting plasma glucose and 1 more. Started Jul 2006; status: terminated.
02
Drugs
MK-0533
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-002090-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002090-47.